-49%

est. 2Y upside i

HealthcareSeries A

We are a frontier AI lab building generative models that capture the fundamentals of biology. We empower partners with breakthrough generative AI to gain unprecedented control over molecular biology, creating new antibodies, optimizing existing enzymes, and advancing genetic engineering.

Rank

#470

Sector

Biotechnology / AI Drug Discovery

Est. Liquidity

~5Y

Data Quality

Data: Medium

Latent Labs presents a strong upside opportunity driven by its cutting-edge generative AI for de novo protein design, a capability that differentiates it from many competitors.

Last updated: March 10, 2026

Bull (30%)+400%

Latent-X2 achieves widespread adoption, securing multiple lucrative partnerships with major pharmaceutical companies and demonstrating superior efficacy in early clinical trials for de novo antibody design. This establishes Latent Labs as a leader in programmable biology, driving its valuation to $1.75B+ within two years.

Base (35%)+70%

Latent Labs successfully expands its Latent-X platform, securing several key partnerships and demonstrating promising preclinical results. Revenue grows steadily, justifying a $600M valuation as a strong, specialized player in the competitive AI drug discovery market.

Bear (35%)-75%

Latent Labs struggles to differentiate against well-funded incumbents like Isomorphic Labs and Generate Biomedicines, leading to slower customer acquisition and a challenging fundraising environment. This results in a down round, reducing valuation to $87.5M and significantly eroding common stock value.

Est. time to liquidity~5.0 years

Preference Stack Risk

moderate

Investors hold $50M in liquidation preferences. If the company exits at or below $50M, common stock holders receive nothing.

Dilution Risk

high

As a Series A company, Latent Labs will likely require several more funding rounds, which will lead to further dilution of existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Latent Labs' equity at this early stage.

Biology — 1 role

Operations — 1 role

View all 14 open roles at Latent Labs →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Latent Labs's data — designed to show you've done your homework.

  • 1

    “How does Latent Labs plan to maintain its differentiation in de novo protein design against well-funded competitors like Isomorphic Labs, especially given their recent $3.5B valuation and AlphaFold capabilities?”

  • 2

    “With the Latent-X2 platform showing promising results, what is the strategic roadmap for securing and scaling partnerships with pharmaceutical companies, and how will these partnerships translate into revenue growth over the next 2-3 years?”

  • 3

    “Given the Series A funding and the long development cycles in drug discovery, what is the company's anticipated timeline for future funding rounds and potential liquidity events for employees?”

Community

Valuation Sentiment

Our model estimates -49% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.